Genotypic and phenotypic predictors of the magnitude of response to tenofovir disoproxil fumarate treatment in antiretroviral-experienced patients.
D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy* / Q000235:genetics; D000225:Adenine / Q000031:analogs & derivatives / Q000627:therapeutic use*; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D018791:CD4 Lymphocyte Count; D004311:Double-Blind Method; D005838:Genotype; D015658:HIV Infections / Q000188:drug therapy* / Q000235:genetics; D054303:HIV Reverse Transcriptase / Q000235:genetics; D015497:HIV-1 / Q000201:enzymology / Q000235:genetics*; D006801:Humans; D015999:Multivariate Analysis; D009154:Mutation; D063065:Organophosphonates; D009943:Organophosphorus Compounds / Q000627:therapeutic use*; D010641:Phenotype; D010919:Placebos; D011237:Predictive Value of Tests; D012367:RNA, Viral / Q000235:genetics / Q000302:isolation & purification; D012044:Regression Analysis; D000068698:Tenofovir; D013936:Thymidine / Q000031:analogs & derivatives / Q000235:genetics
D019380:Anti-HIV Agents; D063065:Organophosphonates; D009943:Organophosphorus Compounds; D010919:Placebos; D012367:RNA, Viral; D000068698:Tenofovir; D054303:HIV Reverse Transcriptase; D000225:Adenine; D013936:Thymidine